TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors.

“I am pleased to welcome Dr. Patane to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. “Mike’s career spans over two decades of leadership experience in drug discovery and development, and he has demonstrated an extraordinary ability to turn scientific success into corporate achievements. His depth of experience and insights will clearly be significant assets to our Board, as we continue to advance our two clinical candidates, TFF VORI and TFF TAC, while seeking to maximize the value of our Thin Film Freezing technology platform.”

“I am happy to join Harlan and his fellow Board members at TFF Pharmaceuticals,” said Dr. Patane. “The team at TFF has established an impressive track record, which includes advancing two clinical-stage assets utilizing their ground-breaking formulation technology, Thin Film Freezing. Optimizing drug formulations to achieve sufficient biodistribution for pharmacological activity is mission critical for the success of any drug development program. Based on earlier Phase 1 data and initial compassionate use cases, Thin Film Freezing has already demonstrated its value in the clinic, and I believe there remains significant untapped opportunity to apply this innovative technology across a broad range of drug development programs.”

Dr. Patane has 25 years of drug discovery and development experience in leadership roles within start-up, biotechnology and global biopharmaceutical companies with broad therapeutic area experience. Most recently, Mike served as President of Mitobridge, Inc. (a wholly owned subsidiary of Astellas), where he oversaw all operations and represented the organization at global interfaces. As part of the pre-Series A team, Mike helped shape the Company’s vision and strategy that culminated in its Series A financing ($45MM), a strategic alliance with Astellas ($30MM non-dilutive) and the acquisition by Astellas ($450MM, $225MM upfront, $338MM currently realized) within four years. Prior to his promotion to President of Mitobridge, Mike served as the company’s Chief Scientific Officer and earlier as its Senior Vice President, Drug Discovery.